Related Experiment Video
Updated: Jun 19, 2026

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)
Published on: August 4, 2023
Microparticles in deep venous thrombosis, antiphospholipid syndrome and Factor V Leiden
M C Flores-Nascimento1, M P Beltrame, E V De Paula
1Hematology-Hemotherapy Center, State University of Campinas, Campinas, SP, Brazil. flores_mariane@yahoo.com.br
Abstract:
Microparticles (MPs) are blebs released from cellular surfaces during activation/apoptosis. They are procoagulant, pro-inflammatory and could contribute to pathogenesis of deep venous thrombosis (DVT). This study compared the number, cellular origin and procoagulant activity of MPs on DVT patients in different clinical situations: at diagnosis (n = 9, 5F/4M; mean age = 41.11), 1-3 years after warfarin withdrawal (n = 10, 7F/3M; mean age = 32.90), associated to antiphospholipid syndrome (APS; n = 11, 9F/2M; mean age = 33.82), or asymptomatic carriers of Factor V Leiden (FVL; n = 7, 7F/0M; mean age = 34.00) vs healthy controls (CTR). The quantification and characterization were performed by flow cytometry using CD235, CD61, CD45, CD31, CD14, CD45, anti-TF and Annexin V. The plasmatic procoagulant activity was investigated by prothrombin fragment 1 + 2 (F1 + 2) determination. The MPs procoagulant activity was analyzed by D-dimer (DD2) and Thrombin Generation Test (TGT) on a healthy pool of plasmas adjusted or not by their number (10,000 MPs). The MPs percentages were not different between the groups, but absolute number was increased in patients 1-3 years after warfarin withdrawal vs CTR (P = 0.02). There was no difference of the MPs cellular origin comparing patients to controls. TGT using 10,000 MPs was lower on these patients (P = 0.01). APS patients showed a reduction of plasmatic procoagulant activity (P = 0.004), but they were under warfarin therapy. DD2 in the presence of MPs, independently of its number, was higher in patients with DVT at diagnosis (P < 0.0001). MPs of patients with spontaneous DVT at diagnosis can promote coagulation activation demonstrated by increased DD2. Even the increased MPs from patients 1-3 years after thrombotic episode generated lower amount of thrombin, they can have a protective effect by activation of Protein C anticoagulant pathway.
Insights
Microparticles (MPs) contribute to deep venous thrombosis (DVT). While elevated in some patients, their procoagulant activity varies, with some potentially offering a protective effect via the Protein C pathway.
Area of Science:
- Hematology
- Vascular Biology
- Thrombosis Research
Background:
- Microparticles (MPs) are cellular fragments linked to thrombosis.
- Their role in deep venous thrombosis (DVT) pathogenesis requires further elucidation.
- Understanding MP origin and activity is crucial for DVT management.
Purpose of the Study:
- To compare MP number, origin, and procoagulant activity in DVT patients across various clinical scenarios.
- To investigate the association between MPs and coagulation activation in DVT.
- To explore potential protective roles of MPs in specific DVT patient groups.
Main Methods:
- Flow cytometry was used for MP quantification and characterization (CD235, CD61, CD45, CD31, CD14, Annexin V, anti-TF).
- Prothrombin fragment 1 + 2 (F1 + 2) measured plasma procoagulant activity.
- D-dimer (DD2) and Thrombin Generation Test (TGT) assessed MP procoagulant activity.
Main Results:
- Absolute MP numbers were elevated in patients 1-3 years post-warfarin withdrawal compared to controls.
- MP cellular origin did not differ significantly between patient groups and controls.
- Antiphospholipid syndrome (APS) patients on warfarin showed reduced plasma procoagulant activity.
- MPs from DVT patients at diagnosis significantly increased D-dimer levels, indicating coagulation activation.
- MPs from patients post-thrombotic episode generated less thrombin but may activate Protein C.
Conclusions:
- MPs from DVT patients at diagnosis promote coagulation activation.
- Elevated MPs in patients after thrombotic events may have a protective role through Protein C activation.
- MP analysis offers insights into DVT pathophysiology and potential therapeutic targets.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Pulmonary Embolism I: Introduction

